Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Increased α2-6 sialylation of endometrial cells contributes to the development of endometriosis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Endometriosis is a disease characterized by implants of endometrial tissue outside the uterine cavity and is strongly associated with infertility. Focal adhesion of endometrial tissue to the peritoneum is an indication of incipient endometriosis. In this study, we examined the effect of various cytokines that are known to be involved in the pathology of endometriosis on endometrial cell adhesion. Among the investigated cytokines, transforming growth factor-β1 (TGF-β1) increased adhesion of endometrial cells to the mesothelium through induction of α2-6 sialylation. The expression levels of β-galactoside α2-6 sialyltransferase (ST6Gal) 1 and ST6Gal2 were increased through activation of TGF-βRI/SMAD2/3 signaling in endometrial cells. In addition, we discovered that terminal sialic acid glycan epitopes of endometrial cells engage with sialic acid-binding immunoglobulin-like lectin-9 expressed on mesothelial cell surfaces. Interestingly, in an in vivo mouse endometriosis model, inhibition of endogenous sialic acid binding by a NeuAcα2-6Galβ1-4GlcNAc injection diminished TGF-β1-induced formation of endometriosis lesions. Based on these results, we suggest that increased sialylation of endometrial cells by TGF-β1 promotes the attachment of endometrium to the peritoneum, encouraging endometriosis outbreaks.

          Endometriosis: a sweet and sticky mechanism uncovered

          A growth factor involved in cell differentiation and proliferation contributes to the development of endometriosis by stimulating a protein modification mechanism that increases the adhesiveness of cells lining the uterus. Endometriosis results when these cells, known as endometrial cells, start growing outside the uterus causing pelvic pain, heavy periods and, in some cases, infertility. Ki-Tae Ha at Pusan National University, Yangsan, South Korea, and colleagues found that transforming growth factor-β1 signaling promoted the addition of sialic acid sugar units onto endometrial cell surface proteins. This modification enhanced the adhesion of endometrial cells to mesothelial cells, which line other internal organs, and the formation of endometriosis lesions in mice. Preventing sialic acid binding to its mesothelial cell receptor reduced lesion formation. The findings reveal a new molecular mechanism underlying endometriosis and a potential treatment strategy.

          Related collections

          Most cited references46

          • Record: found
          • Abstract: found
          • Article: not found

          Pathogenesis and pathophysiology of endometriosis.

          Originally described over three hundred years ago, endometriosis is classically defined by the presence of endometrial glands and stroma in extrauterine locations. Endometriosis is an inflammatory, estrogen-dependent condition associated with pelvic pain and infertility. This work reviews the disease process from theories regarding origin to the molecular basis for disease sequelae. A thorough understanding of the histopathogenesis and pathophysiology of endometriosis is essential to the development of novel diagnostic and treatment approaches for this debilitating condition. Copyright © 2012 American Society for Reproductive Medicine. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Sialic acids sweeten a tumor's life.

            Over four decades ago, specific tumor characteristics were ascribed to the increased expression of sialic acid sugars on the surface of cancer cells, and this led to the definition of sialic acids as potential therapeutic targets. Recent advances in glycobiology and cancer research have defined the key processes underlying aberrant expression of sialic acids in cancer, and its consequences, more precisely. These consequences include effects on tumor growth, escape from apoptosis, metastasis formation, and resistance to therapy. Collectively, these novel insights provide further rationale for the design and development of therapeutic approaches that interfere with excessively high expression of sialic acids in cancer cells. Strategies to target aberrant sialylation in cancer, however, have evolved comparatively slowly. Here, we review recent findings that emphasize the detrimental effects of hypersialylation on multiple aspects of tumor growth and behavior. We also discuss novel therapeutic strategies.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Siglecs as targets for therapy in immune-cell-mediated disease.

              The sialic-acid-binding immunoglobulin-like lectins (siglecs) comprise a family of receptors that are differentially expressed on leukocytes and other immune cells. The restricted expression of several siglecs to one or a few cell types makes them attractive targets for cell-directed therapies. The anti-CD33 (also known as Siglec-3) antibody gemtuzumab (Mylotarg) is approved for the treatment of acute myeloid leukemia, and antibodies targeting CD22 (Siglec-2) are currently in clinical trials for treatment of B cell non-Hodgkins lymphomas and autoimmune diseases. Because siglecs are endocytic receptors, they are well suited for a 'Trojan horse' strategy, whereby therapeutic agents conjugated to an antibody, or multimeric glycan ligand, bind to the siglec and are efficiently carried into the cell. Although the rapid internalization of unmodified siglec antibodies reduces their utility for induction of antibody-dependent cellular cytotoxicity or complement-mediated cytotoxicity, antibody binding of Siglec-8, Siglec-9 and CD22 has been demonstrated to induce apoptosis of eosinophils, neutrophils and depletion of B cells, respectively. Here, we review the properties of siglecs that make them attractive for cell-targeted therapies.
                Bookmark

                Author and article information

                Contributors
                +82-51-510-8464 , hagis@pusan.ac.kr
                Journal
                Exp Mol Med
                Exp. Mol. Med
                Experimental & Molecular Medicine
                Nature Publishing Group UK (London )
                1226-3613
                2092-6413
                12 December 2018
                12 December 2018
                December 2018
                : 50
                : 12
                : 164
                Affiliations
                [1 ]Department of Korean Medical Science, School of Korean Medicine, Seoul, Republic of Korea
                [2 ]ISNI 0000 0001 0719 8572, GRID grid.262229.f, Healthy Aging Korean Medical Research Center, , Pusan National University, ; Yangsan, Gyeongnam 50612 Republic of Korea
                [3 ]ISNI 0000 0001 0719 8572, GRID grid.262229.f, Graduate Training Program of Korean Medicine for Healthy-aging, , Pusan National University, ; Yangsan, Gyeongnam 50612 Republic of Korea
                [4 ]ISNI 0000 0001 2171 7818, GRID grid.289247.2, Department of Life and Nanopharmaceutical Sciences and Department of Oriental Pharmacy, , Kyung Hee University, ; Seoul, 02447 Republic of Korea
                [5 ]ISNI 0000 0001 2181 989X, GRID grid.264381.a, Department of Biological Science, , Sungkyunkwan University, ; Suwon, Kyunggi-do 16419 Republic of Korea
                Author information
                http://orcid.org/0000-0002-6323-0714
                http://orcid.org/0000-0001-6283-0171
                Article
                167
                10.1038/s12276-018-0167-1
                6290765
                30542051
                761dd31d-4c2c-4384-9f47-2a590794ab9b
                © The Author(s) 2018

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 7 November 2017
                : 30 May 2018
                : 12 June 2018
                Funding
                Funded by: FundRef https://doi.org/10.13039/501100003621, Ministry of Science, ICT and Future Planning (MSIP);
                Award ID: NRF-2015R1D1A1A01060264
                Award ID: NRF-2014R1A5A20009936
                Award ID: NRF-2015R1D1A1A01060264
                Award Recipient :
                Categories
                Article
                Custom metadata
                © The Author(s) 2018

                Molecular medicine
                Molecular medicine

                Comments

                Comment on this article